USD
( +0.00%
At Close (As of Jan 1, 1970)
$98.42M
Market Cap
-
P/E Ratio
-0.34
EPS
$2.24
52 Week High
$0.77
52 Week Low
HEALTHCARE
Sector
Field | Value (CAD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$40M |
Selling General And Administrative | $26M |
Research And Development | $14M |
Operating Expenses | $40M |
Investment Income Net | - |
Net Interest Income | $1.2M |
Interest Income | $1.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $162K |
Income Before Tax | -$37M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$37M |
Comprehensive Income Net Of Tax | - |
Ebit | -$40M |
Ebitda | -$40M |
Net Income | -$37M |
Field | Value (CAD) |
---|---|
Total Assets | $32M |
Total Current Assets | $32M |
Cash And Cash Equivalents At Carrying Value | $31M |
Cash And Short Term Investments | $31M |
Inventory | - |
Current Net Receivables | $362K |
Total Non Current Assets | $196K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $727K |
Other Non Current Assets | - |
Total Liabilities | $7.1M |
Total Current Liabilities | $7M |
Current Accounts Payable | $7M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $33K |
Total Non Current Liabilities | $126K |
Capital Lease Obligations | $159K |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $159K |
Other Current Liabilities | $7M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $25M |
Treasury Stock | - |
Retained Earnings | -$179M |
Common Stock | $179M |
Common Stock Shares Outstanding | $72M |
Field | Value (CAD) |
---|---|
Operating Cashflow | -$25M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $373K |
Capital Expenditures | $21K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$21K |
Cashflow From Financing | $19M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$37M |
Field | Value (CAD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$40M |
Selling General And Administrative | $26M |
Research And Development | $14M |
Operating Expenses | $40M |
Investment Income Net | - |
Net Interest Income | $1.2M |
Interest Income | $1.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $162K |
Income Before Tax | -$37M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$37M |
Comprehensive Income Net Of Tax | - |
Ebit | -$40M |
Ebitda | -$40M |
Net Income | -$37M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biotechnology company headquartered in Oakville, Canada, focusing on the development of innovative anti-inflammatory therapies for cardiovascular diseases (CVD). With a strong pipeline supported by advanced research and development efforts, the company is committed to addressing pressing unmet medical needs in CVD treatment. By harnessing leading-edge science and expertise in inflammation, Cardiol Therapeutics aims to deliver novel therapeutic solutions that have the potential to significantly improve patient outcomes globally.